Oak Associates Ltd. OH Sells 2,969 Shares of Jazz Pharmaceuticals PLC $JAZZ

Oak Associates Ltd. OH cut its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 13.7% during the first quarter, HoldingsChannel reports. The fund owned 18,772 shares of the specialty pharmaceutical company’s stock after selling 2,969 shares during the quarter. Oak Associates Ltd. OH’s holdings in Jazz Pharmaceuticals were worth $3,549,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. LRI Investments LLC acquired a new stake in Jazz Pharmaceuticals in the fourth quarter valued at approximately $38,000. Danske Bank A S acquired a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth $40,000. Geneos Wealth Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 137 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Jazz Pharmaceuticals by 1,383.3% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 332 shares during the last quarter. Finally, Leonteq Securities AG purchased a new position in Jazz Pharmaceuticals during the 4th quarter worth $50,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have commented on JAZZ. Needham & Company LLC increased their price target on Jazz Pharmaceuticals from $255.00 to $282.00 and gave the company a “buy” rating in a research note on Monday. Royal Bank Of Canada boosted their price target on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Barclays upped their price objective on shares of Jazz Pharmaceuticals from $253.00 to $260.00 and gave the company an “overweight” rating in a report on Tuesday, July 14th. TD Cowen increased their price objective on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, Piper Sandler increased their price objective on shares of Jazz Pharmaceuticals from $232.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $259.06.

Jazz Pharmaceuticals Trading Up 1.8%

Jazz Pharmaceuticals stock opened at $254.87 on Friday. The firm has a market cap of $16.01 billion, a PE ratio of -12,737.13, a P/E/G ratio of 0.22 and a beta of 0.32. Jazz Pharmaceuticals PLC has a 12 month low of $105.00 and a 12 month high of $255.20. The stock’s 50 day simple moving average is $236.87 and its two-hundred day simple moving average is $202.88. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The firm had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Analysts anticipate that Jazz Pharmaceuticals PLC will post 21.9 earnings per share for the current year.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $240.47, for a total transaction of $1,442,820.00. Following the transaction, the director owned 366,682 shares in the company, valued at approximately $88,176,020.54. This represents a 1.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the sale, the executive vice president directly owned 51,549 shares in the company, valued at approximately $11,950,604.67. The trade was a 2.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 13,098 shares of company stock worth $3,131,906 in the last ninety days. 4.10% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.